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 INTRODUCTION
Diabetes  mellitus  is  a  systemic  disorder  characterized  by 
chronic  hyperglycaemia  and  derangements  in  the  metabolism  of 
carbohydrates,  lipids  and  amino  acids  secondary  to  absolute  or 
relative  deficiency  of  normal  insulin  and  or  insulin  resistance  and 
relative or absolute excess of glucagon. 
Having been recorded as early as 1500 BC in the Abers Papyrus 
of  Egypt,  diabetes  mellitus  is  one  of  the  oldest  diseases  affecting 
mankind.  It  is  now  a  widely  prevalent  global  health  problem.  The 
global  prevalence of  diabetes  in  adult  is  around 4%  (Park K, 2000). 
The  prevalence  is  especially  high  in  India,  which  by  2025  AD,  will  
become the country harbouring the largest  number of diabetics (King 
H et al 1998). 
Every cell in our body rely on the metabolism of carbohydrates,  
aminoacids  and  lipids  for  the  integrity  of  its  structure  and  function. 
The substrates for  the intracellular metabolism are taken up from the 
interstitial fluid and plasma.  The concentration of these substrates in 
these  fluids  depends  to  a  great  extend  on  the  metabolism by  insulin 
sensitive tissues such as  hepatocytes,  adipocytes,  myocytes  etc.  Thus 
the  insufficiency  of  insulin  action  in  diabetes  mellitus  indirectly 
affects  every  cell  in  the  body  besides  directly  affecting  the 
metabolism of insulin dependent cells.
Diabetes  mellitus  is  a  syndrome  which  has  metabolic  and 
vascular  components.  The  metabolic  component  consists  of 
derangement  in  the  metabolism  of  carbohydrates,  lipids  and 
aminoacids.  (Ronald  Kahn  C,  Gordon  C  Weir,  1996).  The  vascular 
component consists of accelerated atherosclerosis, capillary basement 
membrane  thickening,  hyperplasia  of  endothelial  cells,  occlusion  of 
capillaries,  hyperfiltration,  microaneurysm  formation  and 
neovascularisation.
Diabetes  mellitus,  being  a  chronic  disease,  causes  a  variety  of 
complications,  which  account  for  the  great  morbidity  and  mortality 
due  to  this  disease.  The  complications  of  diabetes  mellitus  include 
diabetic  ketoacidosis,  nonketotic  hyperosmolar  coma,  neuropathy, 
retinopathy,  nephropathy,  atherosclerosis,  hypertension,  ischaemic 
heart  disease,  peripheral  vascular  disease,  stroke,  decrease  in 
immunity,  increased  susceptibility  to  infections,  teratogenicity  and 
intrapartum complications.   With  the better understanding and better 
methods  of  management,  the  lifespan of  diabetic  patients   have been 
lengthened  to  a  great  extent  and   so  the  incidence  of  long  term 
microvascular and macrovascular complications have also increased. 
Neuropathy  is  the  commonest  diabetes–specific  complication. 
Neuropathy is  known to occur even with a  short  duration of  diabetes 
mellitus.  Many  of  these  patients  lack  symptoms  and  signs  of 
neuropathy  i.e.,  subclinical  diabetic  neuropathy  is  common  (Akbar 
DH et  al,  2000).1 It  is  often  undiagnosed  for  a  long period  until  the 
patient  develops  clinical  features  suggestive  of  sensory,  motor,  or  
autonomic  dysfunction.  Electrophysiological  investigations  such  as 
nerve  conduction  studies  are  sensitive  in  detecting  the  presence  of 
asymptomatic neuropathy
Diabetic  neuropathy  primarily  affects  the  peripheral  nervous 
system,  including the  cranial  nerves  (Aminoff,  1989) (2).  Though it  is 
often peripheral  neuropathy that  we diagnose in the diabetics (Daniel 
Tarsy)  the  involvement  of  the  central  nervous  system  has  also  been 
well-documented  (Das T, 20013;  Eaton SE4).   Only few studies have 
so  far  been  conducted  regarding  prevalence  of  central  nerve 
conduction abnormalities.
Evoked  potentials  is  a  convenient   and  non  invasive  tool  for 
evaluation of  central  nervous  system Visual  evoked potentials  (VEP) 
could  be  used  to  evaluate  disturbances  in  the  central  visual  pathway 
(5,6,7) Fullfield VP is excusitively sensitive to lesion of optic nerve and 
anterior chiasma. 
Evoked  potentials  are  also  helpful  in  determining  subclinical 
lesions in the optic nerve, spinal cord & brain stem.  Therefore it is a 
convenient  tool  in  the  diagnosis  and  follow  up  for  neurological 
disorders (8,9,10).  
In diabetes mellitus,  Visual  deficits  appears to result  from both 
Vascular disease and metabolic abnormalities, which can affect retina, 
optic  nerve  and  Visual  pathway.  There  are  conflicting  results 
regarding  optic  neuropathy  in  diabetic  patients.   Tests  for  optic 
neuropathy  have  been  performed  in  children  and  adult  on  a 
comparatively  small  scale (5).  Therefore  the  aim of  present  study  was 
to  evaluate,  Visual  evoked  potentials  in  diabetic  patients  and  if 
altered its relationship with peripheral neuropathy.
VEP  is  primarily  a  reflection  of  activity  originating  in  the 
central 3 to 6° of Visual field which is relayed to surface of occipital 
cortex.  All  portions  of  PVEP are  probably  of  cortical  origin  and  are 
classified  as  middle  latency  evoked  potential.  However  the  exact  
source  of  different  PVEP  components  are  unresolved.  The  earliest 
definable  wave  P50  begins  within  50  ms.   N  75  may  represent  the 
initial  excitation associated with the arrival  of  Visual  Signal  at  layer  
of  IV of  the calcarine cortex.   Kraui  et  al  proposed that  P 100 arises 
from a  secondary  wave  of  inhibition  of  pyramidal  cells  mediated  by 
GABA.   Experiment  with  magnetic  interference  over  the  occipital  
cortex  indicate  that  the  interval  from  80  to  100  ms  after  a  retinal 
stimulation  is  critical  for  Visual  perception.   This  time  frame 
correlates  well  to  P  100  and  suggests  that  later,  does  in  some  way 
reflect active processing of Visual information.
TRANSIENT VEP & STEADY STATE VEP
When  the  interval  between  Visual  stimuli  is  greater  than  the 
duration of the VEP & responses are averaged immediately the result  
is  called  transient  VEP.  This  is  the  type  generally  used  in  clinical  
situation. 
At stimulus faster than 4 / sec, sequential VEP run together and 
form  train  of  rhythmic  activity  called  steady  state  VEP.  Used  to 
measure visual acuity objectively.
VEP STIMULUS
1) Pattern  reversal  –  the  most  commonly  used  stimuli  for  VEP 
recording  is  a  pattern  of  light  and  dark  check,  bar  or  strips  that  is  
repeatedly  reversed.  Most  clinical  lab  use  black  and  white  checker 
board pattern.  Evoked potential guideline of ACNS 
(American  Clinical  Neuro  physiology  society)  recommend  a  check 
size  in  the  range  of  24  –  32  minutes  of  arc.  At  this  size  effects  of 
Visual blurring reduced and foveal sensitivity remains high.
2) Flash evoked potential .  Cortical response to flash stimuli is much 
more  wide  spread  complex  and  variable  than  that  resulting  from 
pattern  shift.  The  great  variability  of  FVEP limit  their  utility.  FVEP 
can  be    recorded  through  closed  eye  and  through  all  but  the  most 
dense ocular opacities.  It is unaffected by refractory errors, so useful 
in  assay  of  function  of  optic  nerve  and  central  visual  pathway  in 
patients with ocular scarring and hemorrhage.  
Retrochiasmatic lesions are not often detected by fullfield VEP. 
Hemifield techniques increase the sensitivity of VEP to retrochiasmal  
lesions.
P 100 LATENCY 
P 100 response as  part  of  VEP wave from, is  an average,  event 
related brain electrical potential. It derives its name from the fact that  
it occurs 100 ms after the stimuli onset. The choice is not attributable 
to any special physiologic significance of P 100. It  is simply one that 
is  highly  consistent  and  reproducible  wave  form  (11,  12,13) which  is 
generated  in  the  striate  and parastriate  visual  cortex in  response to  a 
visual stimuli.
Current  methods  of  clinical  assessment  using  this  wave  form 
require  the  subject  to  look  at  a  checker  board  which  is  a  more 
sensitive than flash method.  The position of its maximal amplitude is 
variable  occuring,  at  the  ionion  in  some  individuals  and 
corresponding  to  electrode  position  of  Oz  in  the  standard  10-20 
electrode placement system. In other subjects amplitude is greatest in  
the  midline  parietal  region  (Pz).  Therefore  in  standard  clinical 
measurement waveforms are recorded both at Oz and Pz. The majority 
of  the  P  100  waveform  is  generated  by  the  lower  half  of  the  visual 
field and a number of variables will influence the resultant waveform,  
such as  visual  angle subtended by the stimulus and the size of  check 
on the checkerboard,  Luminance and ambient  room illumination. The 
P  100 is  greatest  in  children  during  the  first  decate  of  life  declining 
thereafter  to  remain  at  a  lower  level  that  is  stable  throughout  adult  
life.  P  latency  increases  in  people  over  60  years  of  age.  The  P  100 
latency  has  better  correlation  with  head  circumference  than  with 
gender and no significant correlation of P100 with head length.
TECHNICAL RECOMMENDATIONS FOR VEP STUDY
Channel 1 0Z – FPZ
Channel 2 0Z – A1A2
Ground CZ
Recording condition
Band pass 1 – 300 Hz
Analysis time 250 ms
No.of  epochs – atleast 100
STIMULATION
Black & White checker board or vertical grating.
Contrast 50 – 80%
Full field size  > 8°
Size of pattern 14 X 16 min
Rate of stimuli 1 Hz (transient) 
4 – 8 (steady state)
Mean luminance of central field 50cd / m2 
Background luminance 20 – 40 cd /m2.
NORMAL VEP
 Left Right
 DIABETES MELLITUS AND ITS COMPLICATIONS
Diabetes  mellitus,  being  a  systemic  endocrine  disorder;   is  a 
disease  involving  all  organ  systems  of  the  body.  It  is  a  disorder  of  
energy  metabolism  with  a  significant  deleterious  impact  on  the 
nervous  system.  With  the  increase  in  the  prevalence  of  diabetes  and 
the  increase  in  the  lifespan  of  diabetics,  the  long  term  degenerative 
complications  of  diabetes  are  increasingly  becoming  a  global  public 
health problem.
P100
P100
The complications  of  diabetes,  as  classified  by Jean D.  Wilson 
et al in 1998 are: 
I. Acute metabolic complications 
1. Diabetic Ketoacidosis 
2. Nonketotic hyperosmolar coma 
II. Degenerative complications
3. Microvascular  complications  (microangiopathy  and  its 
sequelae)
a. Neuropathy 
b. Retinopathy 
c. Nephropathy 
2. Macrovascular complications:- 
(1) Hypertension 
(2) Ischaemic heart disease 
1                (3) Cerebrovascular accidents 
  (4) Peripheral vascular disease
III. Miscellaneous complications such as
Impairment of immunity
Foetal macrosomia, lung immaturity
Intrapartum and postpartum complications 
Diabetes  is  a  common cause of  disability and death through its 
complications  Data  from  Chennai  show  that  the  prevalence  of 
complications  of  type 2 diabetes  mellitus  are  high (Ramachandran A 
et al, 1999) as follows: 
Hypertension 38.2% 
Peripheral neuropathy 25.5%
Retinopathy 23.7% 
Coronary heart disease 11.4% 
Nephropathy 5.5%
Peripheral vascular disease 4%
Cerebrovascular accidents  0.9% 
In general,  the complications and their pathogenesis seem to be 
similar in type 1 diabetes mellitus and type 2 diabetes mellitus.
Diabetic Neuropathy 
Diabetic  Neuropathy  is  defined  as  the  presence  of  symptoms 
and  or  signs  or  other  objective  evidence  of  peripheral  nerve 
dysfunction  in  diabetics  after  exclusion  of  other  causes  (Boulton 
AJM et al, 1982).12 Most authors use the term diabetic neuropathy as 
a  synonym  for  diabetic  peripheral  neuropathy  because  most  of  the 
neurologic  complications  of  diabetes  mellitus  involve  the  peripheral 
nervous system including the cranial nerves. 
The estimated prevalence of diabetic neuropathy varies with the 
sensitivity of the diagnostic methods and the type of patients studied. 
Pirart  J  reported  a  prevalence  of  7.5%  at  the  time  of  diagnosis  of  
diabetes  mellitus.  The  prevalence  increases  with  the  duration  and 
severity  of  hyperglycaemia  to  affect  60-75%  of  the  diabetics  during 
the course of diabetes. Neurophysiological techniques have revealed a 
higher  incidence of  70-90% (Gallai  V et  al,  1988).  Thus,  neuropathy 
is the commonest microvascular complication of diabetes. 
Classification of Diabetic Peripheral Neuropathies
The complexity of clinical presentation as well as the imprecise 
information  on  the  pathophysiology  make  the  classification  of 
diabetic  neuropathies  difficult  and  imperfect.  Considering  the 
topographic distribution, the mode of onset  and progression, the type 
of  nerve  fibres  affected,  and  the  nature  of  dysfunction,  diabetic 
peripheral neuropathies may be arbitrarily classified into
I. Acute symmetrical polyneuropathies 
1. Acute painful neuropathy
2. Rapidly reversible neuropathies. 
(i)   Hyperglycaemia induced/ hyperglycaemic neuropathy 
(ii) Treatment induced neuropathy 
II. Chronic symmetrical polyneuropathies
1. Distal  sensory  ±  autonomic 
polyneuropathy
2. Distal  sensori  -motor 
polyneuropathy
3. Large fibre neuropathy
4. Small fibre neuropathy
5. Autonomic neuropathy
6.      Symmetric proximal lower 1imb motor neuropathy
7.      Chronic Inflammatory Demyelinating Polyneuropathy 
III. Asymmetrical focal or multifocal neuropathies 
1.  Diabetic  amyotrophy  (Asymmetric  proximal  lower  limb  motor 
neuropathy)
2. Mononeuropathies
(1). Cranial neuropathy (single or multiple)
(2).  Truncal  neuropathy  (Thoracoabdominal  radiculopathy/ 
plexopathy)
                (3).   Lumbosacral radiculoplexopathy
    (4). Focal limb neuropathies (limb mononeuropathy- single or 
multiple)
(i) Mononeuritis multiplex
(ii) Entrapment neuropathies
IV. Combinations
1.  Polyradiculoneuropathy
2.  Diabetic neuropathic cachexia
Diabetic cranial nerve palsies
Vascular infarct with resulting ischaemia is considered to be the 
cause of diabetes-related cranial nerve palsies. The third cranial nerve 
is the most commonly affected. The sixth, fourth, seventh cranial and 
optic  nerve  may  also  be  affected.  Diabetes  induced  third,  fourth  and 
sixth  nerve  palsies  are  self-limited.  The  complete  recovery  from 
oculomotor  palsy  within  three  months  indicates  that  focal 
demyelination without axonal destruction is the responsible lesion.
Aetiopathogenesis of Diabetic Neuropathy 
The  aetiological  role  of  diabetes  mellitus  in  neuropathy  has 
been  proved  beyond  doubt.  Most  of  the  neurologic  complications  of 
diabetes involve the peripheral  nervous system.  Diabetes is known to 
cause central nervous system dysfunction also. 
The pathogenesis of diabetic neuropathy  is  not precisely known 
despite  recent  advances.  So  several  hypotheses  have  been  put 
forward. These hypothesis can be broadly classified into:- 
1. Ischaemic /hypoxic hypothesis 
a. Haemodynamic hypothesis
b. Microvascular hypothesis 
c. Prostaglandin hypothesis 
d. Hypercoagulability hypothesis 
2. Metabolic hypotheses 
a. Axonal hypothesis
b. Schwann cell hypothesis 
c. Osmotic hypothesis
d. Myoinositol depletion hypothesis
e. Overglycation hypothesis
f. Oxidative stress hypothesis 
g. Deranged lipid metabolism hypothesis
h. Taurine depletion hypothesis
i. Magnesium deficiency hypothesis
j. Carnitine deficiency hypothesis
3.     Impaired neurotrophism hypothesis
Neurotrophin deficiency hypothesis
4.  Autoimmune hypothesis 
The  present  day  diabetologists  and  neurologists  favour 
the microvascular hypothesis (Singh & Gupta,  2002).  But the general  
consensus  is  that  diabetic  neuropathy  is  a  disease  of  multifactorial 
aetiology,  the  various  pathogenic  factors  acting  synergistically 
(Feldman EL et al, 1997). 
REVIEW OF LITERAUTRE
The  significance  and  prevalence  of  diabetic  neuropathy  has 
increased in recent years because of the increase in the prevalence of 
diabetes  mellitus.  The  increase  in  life  span  of  diabetics  and  the 
availability of more sensitive methods of detection of neuropathy.
According  to  WHO,  19%  of  world  diabetic  population  is  in 
India. Present diabetic population of 35 million projected to go up by 
80 million by 2030.
Boulton AJM et  al  (1982) 12  defined  diabetic  neuropathy as  the 
presence  of  symptoms  and  or  signs  or  other  objective  evidence  of  
peripheral  nerve  dysfunction  in  diabetes  after  the  exclusion  of  other 
causes for the peripheral neuropathy. The presence of certain diabetic 
complaining  of  sensory  symptoms  even  when  physical  and 
electrophysiological  examination  reveal  to  neurological  abnormality, 
made  it  necessary  to  redefine  the  term.  So  in  the  San  Antonio 
conference  of  Diabetic  Neuropathy,  The  American  Diabetic 
Association  and  the  American  Academy  of  Neurology  came  to  a 
consensus  that  diabetic  neuropathy  is  a  descriptive  term  meaning 
demonstrable  disorder,  either  clinically  evident  or  subclinical,  that 
occurs  in  the  setting  of  diabetis  mellitus  without  other  causes  for  
peripheral neuropathy.
More  recently,  electrophysiological  investigation  have 
demonstrated  the  presence  of  chronic  diabetic  neuropathy  affecting 
the  central  nervous  system.  Hence  it  is  advisable  to  use  the  term 
diabetic  neuropathy in  a  broader  prespective  to  designate  all  chronic 
neurologic manifestation (central as well as peripheral) of diabetes.
History of Neurodiabetology
   In  1975,  when  Rou  J13 become  the  first  person  to  document 
symptoms of peripheral neuropathy in diabetic patients. The next 100 
years saw many relevant works on neurodiabetology which contained 
valuable descriptions relating to symptomolocolgy of  nervous system 
damage in diabetes.
In  189314 Pyre  TD observed  that  the  neurological  disturbances 
in  diabetic  patients  were  associated  with  pathological  changes  of  
peripheral nerve at autopsy.
In  1950  a  great  number  of  works  were  published,  in  which 
correlation  of  nervous  system  was  studied  by  electrophysiological, 
histochemical,  electron  microscope  biochemical  and  other  methods. 
This  enabled  the  development  of  a  detailed  clinicophysiological 
picture  of  various  types  of  diabetic  neuropathy,  and  also  revealed 
certain mechanisms responsible for central and peripheral neuropathy.
Recently electrophysiologcal screening of central and peripheral 
nervous  system  involvement  and  many  interventional  studies  using 
essential  fatty  acids,  antioxidants,  neurotrophins,  genetherapy  and 
various other drugs are being conducted in different part of world.
Prevalence of diabetic peripheral neuropathy
The  neuropathy  that  we  often  diagnose  in  the  diabetes  is 
peripheral neuropathy (Daniel Tarssy and Roy Freeman 1996).
The most  comprehensive study of  the incidence and prevalence 
of  neuropathy  in  a  diabetic  population  was  the  prospective  study  on 
4400  diabetics  during  1947  to  1973  conducted  by  Piart  J.  The 
prevalence  of  neuropathy  was  7.5%  at  the  time  of  diagnosis  which 
increased more or less linearly at the rate of about 1.7% / year to 20 – 
30% after 10 – 15 years and to 50% after 25 years.
Pyrce  PJ  et  al  (1993)  have  reported  that  neurological 
complications  occur  equally  in  Type  I  and  Type  II  diabetes  and 
additional  in various forms of  acquired diabetes  mellitus.  But  United 
Kingdom multicentric  study  (Yound  NJ  et  al)  showed  the  peripheral 
neuropathy was more common in Type II.
Cabezas  Cerrato  J  (1998) 15 carried  out  a  multiregional  cross 
sectional  study  of  clinical  diabetic  poly  neuropathy  among  2644 
Spanish  diabetic  patients.  Using  a  standard  system  for  scoring 
symptom  and  signs  of  polyneuropathy  the  prevalence  of  diabetic 
neuropathy  was  found  to  be  22.7%  in  the  whole  sample,  12.9%  in 
Type  I  diabetes  and  24.4% in  Type  II  diabetes.  The  prevalence  was  
14.2% among diabetes < 5 years.
Nihalani  KD  et  al 16 (1999) reported  an  overall  prevalence  of 
peripheral  neuropathy of 55.6% among non geriatric Indian diabetics. 
A  Chennai  based  study  by  Ramachnadran  A.  et  al  (1999)  revealed 
that  the  prevalence  of  peripheral  neuropathy  in  type  II  diabetes  was 
25.5%  and  that  the  neuropathy  was  the  commonest  microvascular 
complication.
In the study by De Wyh Ch and Colleagues (1999) on Australian 
outpatients  attending  a  diabetic  clinic,  polyneuropathy  defined  as 
Lower Limb Sensory and motor nerve conduction velocity on latency 
outside  ±  25D of most measured in age matched control, was present 
in 40% of patients.
Vinik  A(1999)17 et  al  has  reported  that  among  the  patients 
attending a diabetic clinic 25% had symptoms of neuropathy 50% had 
signs  of  neuropathy  revealed  by  simple  clinical  host  such  as  ankle 
jerk  or  vibrator  preparation  test  and  almost  90%  tested  positive  to 
sophisticated tests of antonomic function or peripheral sensation.
 Ashok S et al (2001)18 determined the prevalence of peripheral 
neuropathy using biothesiomtry in a large group of South Indian type 
2  diabetes  in  Chennai  19.1%  of  patients  had  evidence  of  peripheral 
neuropathy.  The prevalence of  neuropathy increased with increase in 
the age and duration of diabetes.
Barbosa et al (2001)19 studied 93 type 2 diabetes in Portugal 72 
(80%) patients had symptoms of polyneuropathy but clinical  signs of 
distal  symmetric  polyneropathy  was  present  only  in  29  (32.2%) 
significant  positive  association  with  age,  duration,  feet  skin  changes 
and myocardial resistance.
Central neuropathy in diabetes mellitus
Though  neurons  do  not  require  insulin  for  glucose  uptake. 
Insulin  acts  on  nervous  system.  Insuline  receptors  are  widely 
distributed  in  the  brain.  They  are  also  present  in  the  peripheral  
nervous system.
A  number  of  autopsy  studies  have  documented  spinal  cord 
lesions in diabetics (De Jorg RN 1976). Autopsy studies conducted by 
Ohnishi  A et  al  (1983)22 revealed degeneration  of  posterior  column, 
which probably was secondary to disease of dorsal root ganglia or the 
peripheral  nerves.  Eaton  and Colleagues  (2001)23 using  MRI  found 
that  diabetics  having  distal  symmetrical  polyneuropathy  had 
significant  smaller  cord  area  at  C4/5  and  T3/4  when  compared  to 
healthy  controls.  This  indicates  distal  symmetric  polyneuropathy  is 
not  simply  a  disease  of  the  peripheral  nerve,  but  there  is  substantial  
involvement of the spinal involvement of the spinal cord. Olssen et al  
(1968) have  correlated  the  corticospinal  tract  degeneration  10 
diabetics to lesion higher in the nervous system.
An  Indian  study  by  Das  et  al  (2001)  has  revealed  that 
subclinical  dysfunction  of  central  nervous  system  is  common  in 
diabetes,  particularly  in  NIDDM  and  this  can  reliably   detected  by 
measuring  sensory  evoked  potential.  57  IDDM and  NIDDM patients 
and  25  controls  who  were  found  to  be  absolutely  normal  by  clinical  
examination  of  CNS  and  computerized  tomogram  of  brain  were 
selected for  the study.  Reduced VEP was found in 16.7% of NIDDM 
and 11% of IDDM.
Mariani  E.  etal  (1990)22 found  prolongation  of  P100  latency 
significantly  longer  in  diabetics  with  polyneuropathy  than  those  in 
without,  particularly after binocular stimulation. He had studied VEP 
in  35  patients  without  retinopathy  (4  IDDM + 31  NIDDM).  Positive  
correlation  was  found  between  latencies  of  VEP  and  HbAI  and 
duration of diabetes.
ALgan  et  al  (1989)5 evaluated  50  IDDM  and  19  NIDDM  and 
reported p100 latency above normal n 28% of them. P100 latency was 
significantly larger in patients with diabetes. There was no correlation 
between  P100  latency  and  type,  duration  of  diabetes,  quality  of 
metabolic control or presence of degenerative complication.
Puvanendran K et  al  (1983) 6 reported abnormal PVEP in 10 of 
diabetic patients and suggested this could be a confusing factor in the 
diagnosis of multiple sclerosis.
Ponte  F  et  al  (1986)23 studied  VEP  in  62  IDDM  without 
retinopathy  and  attempted  to  correlate  the  duration  of  diabetes, 
insulin  requirements,  blood glucose  and  glycosylated  Hb with  VEPs. 
He found prolongation of P100 latencies in diabetes and VEP detected  
by  small  check  was  more  involved.  Positive  correlation  was  found 
between VEP and duration of diabetes.
D criillo  et  al  (1984)24 reported  significant  VEP  abnormalities 
in 30% of subjects  he studied.  He studied VEP in 30 IDDM children 
and  adolescent.  No  correlation  was  found  between  VEP  and  age,  
duration of diabetes and metabolic control and retinopathy.
Maritinelli et al (1991)25 using electrophysiological tests (ERG, 
VEP,  Oscillatory  potential)  studied  function  of  visual  system  in 
IDDM.  He  studied  10  IDDM &  10  control  subjects  before  and  after 
photostress  and suggested  by the  presence of  impaired  basal  VEP an 
early  involvement  of  nervous  condurtance  in  optic  nerve.However 
preserved  flash  ERG  and  normal  recovery  time  after  photostress,  
indicated a short disease duration does not induce physiopathological 
changes in the outer retinal layers or in the macular function.
Yalt  Kayak  et  al  (1988)26 looked  into  whether  there  is  a 
peripheral  and central  involvement  of  nervous system.  He studied 30 
normal  subjects  and  25  diabetics  in  whom  apart  from  VEP,  Sural 
nerve  conduction  velocity  was  also  determined.  He  found 
prolongation  in  P100  and  N140  components.  The  N90  –  140  inter 
peak Latency was also prolonged. Pathologic changes in VEP did not 
show any correlation with sural nerve conduction abnormalities.
O  Ziegler  et  al  (1994)27 found  short  term  blood  glucose 
normalization  improved  P100  latency  in  uncomplicated  diabetic 
patients  and  suggested  abnormal  VEP  are  partially  reversible  and 
include  functional  disturbance  related  to  glucose  metabolism.  He 
studied 12 poorly controlled. Diabetic patients before and after 3 days 
of  near  normoglycemia  obtained  by continuous  insulin  infusion.  The 
p100 latencies were longer in diabetics. After 3 days of blood glucose 
control the mean P100 latencies were significantly shorter.
G.Pozzesseere  et  al  (1988) 28 reported  that  neurophysiological 
abnormalities  are  present  at  different  levels  in  IDDM  and  NIDDM 
patients  only  a  few  years  after  clinical  diagosis  and  before  the 
appearance of overt complications and these abnormalities seem to be 
correlated with metabolic control status. He recorded VEP, BAER and 
SEP in 4 groups,  group1 – 11 IDDM, group 2 – 14 NIDDM, group 3 
and 4 control group. In group 1 and 2 significant abrnormalities were 
found in the latency values of VEP.
G Pozzcssere et al (1991)29 found evidence that higher cognitive 
function may be affected in diabetes as documented by P300 analysis  
and  short  term memory  test.  Electrophysiological  analysis  highlights 
neuropsychological  changes  not  detectable  by  psychometric  tests. 
Alteration  of  evoked  potential  was  present  in  half  of  IDDM subjects  
studied.  VEP,  BAER,  SEP  was  carried  in  16  IDDM  patients. 
Abnormal VEP was recorded in 1/16.
G.Tamburrano  et  al  (1988)30 demonstrated  that  earliest 
hypoglycemia  induced  EEG  alterations  occur  in  the  frontal  regions 
and VEP is less effective. He studied the effects of hypoglycemia per 
se on EEg and VEP in 8 normal young patients.
KJ  Hardy  et  al  (1995)31 suggested  that  short  term  changes  in 
blood glucose  are  not  the  mechanism for  visual  pathway dysfunction 
in  aretinopathic  IDDM  patients  as  hypothesized  by  many.  Colour 
discrimination  was  measured  in  10  uncomplicated  aretinopathic 
IDDM patients during hyperglycemic,  euglycemic  and hypoglycemic 
state and there was no difference.
Uberall MA (1996)32 assessed 29 adolescents with IDDM and 29 
controls steadily increasing latency delay for VEP (N80, P100, N150, 
P200)  and  ERP  components  in  IDDM  group  was  found.  A 
pathological  VEP/ERP  latency  delay  of  more  than  3SD  above  the 
reference value range was observed in 21 IDDM patients (72.4%).
Alessandrini  M  et  al  33 evaluated  whether  correlation  existed 
between  saccadic  eye  movements  and  visual  pathways  function  in 
diabetic patient.  Saccadic or fast  eyemovement (EMS) and VEP were 
assessed in 20 IDDM. VEP showed a significant delay in N75, P100, 
N145, latencies and significant reduction of N75 100 and P100 N145 
amplitudes.  No  relationship  was  found  between  saccadic 
eyemovement and VEP abnormalities.
Parsi  et  al  (1994)34 studied  VEP  after  photostress  in  IDDM 
patients  with  or  without  retinopathy.  VEP  recorded  under  basal 
conditions  showed  a  P100  latency  significantly  higher  in  IDDP  and 
IDDP WR  than  in  control  eyes  and  in  IDDPWR  than  in  IDDP eyes.  
N75 – P100 amplitude was significantly lower in diabetic compared to 
control.  In  all  eyes  VEP  after  photostress  showed  an  increase  in 
latency and decrease in amplitude.
Dolu H (2003)35 evaluated central neuropathy in type II diabetes 
mellitus  by  multimodal  evoked  potential  and  concluded  that  central 
and peripheral  neuropathies  in  DM are  related  to  the  duration  of  the 
disease and not to degree of hyperglycemia and metabolic control.
Lip  Yang  Y36 explained  the  alteration  of  PVEP  in  30  NIDDM 
patients  and  compared  with  30  cases  of  healthy  subjects.  The 
abnormality  of  PVEP  is  related  to  blood  sugar  in  empty  stomach 
course of NIDDM, peripheral nerve lesions and diabetic neuropathy.
U  CCicoli  L  et  al  (1995) 36 assessed  visual  function  in  newely 
diagnosed IDDM patients electrophysiologically. In 10 IDDM patients 
and 10 controls he studied ERG, oscillatory potential & VEP in basal  
condition  and  after  photostress.    The  VEP  under  basal  condition 
showed  that  P100  latency  was  significantly  increased  in  diabetic 
patients  compared  to  control.  The  impaired  basal  VEP  suggests  an 
early involvement of nervous conduction in optic nerve.
Martinelli  V  (1992)38 evaluated  effects  of  hyperglycemia  on 
VEP  in  10  IDDM  patients  in  10  patients  and  suggested  that. 
neurophysiologic abnormalities  detected in IDDM patients are due to 
structural  involvement  of  central  nervous  pathways  and  not  due  to 
functional damage induced by acute short term hyperglycemia.
Pan CH et  al  (1992)39 conducted  PSVEP study on  46  cases  of 
NIDDM  and  13  cases  of  IDDM.  The  peak  latency,  IPL  and  evoked 
amplitude  of  P100  were  analysed.  Motor  and  sensory  nerve 
conduction  velocities  of  the  median  nerve,  blood  sugar,  HbA1c  and 
duration  of  DM  were  measured  simultaneously.  Prolongation  of  all  
peak latency and IPL and decreased amplitude of P100 were found.
Fierro  B  et  al  (1996)40 evaluated  central  nervous  system 
involvement  in  diabetes,  IDDM  >  10  years  duration  using  SEP  and 
VEP.  Both  parameters  were  abnormal  in  10(28%)  patients.  VEP and 
SEP components  were not  generally  significantly associated  with the 
indices of peripheral function.
Khardori R et al (1986)41 measured VEP and BAER in 34 type I 
diabetic  patients.  15%  had  abnormal  VEP.  These  abnormalities  was 
not  related  to  duration  of  diabetes,  diabetic  control  or  individual 
diabetic complications.
Comi G et  al (1981)42 investigated for central  neuropathy in 71 
IDDM type  I  diabetic  children  & 33  controls.  The  P100  latencies  of 
P100  were  significantly  lengthened  in  17  patients  (27%)  but  no 
correlation  was  found  between  VEP  and  age,  duration,  insulin 
requirements  and  HbA1  level.  Negative  correlation  was  found 
between VEP and peripheral nervous conduction velocity.
Moreo  G  et  al  (1995)43 performed  longitudinal  study  in  18 
NIDDM  patients  and  35  control.  At  first  recording  the  peak  P100 
latency  were  significantly  delayed  in  diabetic  and  peripheral 
neuropathy  was  detected  in  5.  The  second  recording  no  significant 
alteration  in  P100  but  peripheral  neuropathy  increased  to  7.  He 
concluded VEP abnormalities remain stable and peripheral neuropathy 
progressed.
Verrotti A et al (2000)44 suggested that glycemic control reverse 
VEP  abnormalities.  VEP  was  recorded  before  and  after  photostress. 
HbA1c  was  9.4% P100  latency  was  significantly  prolonged  and  test 
repeated  6  months  later  with  good  glycemic  control  HbA1 7.2%.  At 
second  recording  a  complete  normalization  of  parameters  was 
observed.
  Collier  A  et  al  (1988) 45 using  SEP  and  VEP  looked  for 
evidence  for  central  neuropathy  in  IDDM  with  mild  peripheral 
neuropathy. The VEP showed a small but significant delay.
Aguggia  et  al46 looked into  correlation  of  VEP polyneuropathy 
in diabetic patients without retinopathy. Among 35 patients (4 IDDM 
and  31  NIDDM)  VEP  was  studied  and  four  peripheral  nerve 
conduction  velocity  (sensory  and motor  conduction  of  median nerve, 
peroneal  nerve  and  sural  NCV).  Delay  in  cerebral  evoked  potential 
was mostly attributable to the peripheral  neuropathicv change and no 
firm evidence was in favour of central diabetic neuropathy.
  Parisi  et  al  (1998)47 assessed whether  VEP abnormalities  are 
due to impaired function of retinal layers and or delayed. Conduction 
in  post  retinal  visual  pathway.  Simultaneous  recordings  of  VEP  and 
PERG were performed at 2 intervals, at entry and 3 months later in 14 
newly diagnosed IDDM patients. In comparison to controls VEP P100 
latencies,  significantly  delayed,  impairment  of  all  PERG  parameters 
and  retinocortical  time  and  latency  window.  No  correlations  were 
found  between  the  paratmeters.  The  two  sources,  one  retinal 
(impaired  PERG)  and  one  post  retinal  may  independently  contribute 
to the abnormal VEP.
Akinci et al (1994)48 studied BAER, VER and NCV in 18 IDDM 
patients.  VER  latencies  were  prolonged.  There  was  a  positive 
correlation  between  NCVs  of  n.peroneal  and  median  (motor  and 
sensory) and VER latencies.
Millingen  (1987)49 KS  et  al  performed  PVER  in  60  diabetic 
inpatients.  Only  one  patient  had  unequally  prolonged  VER  and  2 
others  it  was  prolonged  unequally  in  association  with  proliferative 
retinopathy. The study does not strongly support the concept of optic 
neuropathy.
Anastasi  M et  al  (1985) 50 studied  VER in  50  diabetics  IDDM. 
The latency was prolonged in relation to duration of the disease.  The 
VEP alteration probably indicate alteration of membrane imbalance or 
demyclinisation.  
Pozzessere  G  (1989)51 performed  a  longitudinal  study  in  9 
IDDM  and  12  NIDDM.  At  first  recording  abnormalities  present  in 
both  type  I  and  II.  In  follow  study  the  number  of  patients  with 
pathological  values  remained  unmodified,  a  tendency to  progression, 
namely  the  number  nervous  level  with  electrophysiological 
abnormalities was observed.
Thomas SV et al (1993)52 evaluated P100 latency in 20 patients 
with  Tropical  pancreatic  diabetes  and  20controls.  No  statistically 
significant difference in P100 latency between the two groups.  There 
was no correlation between P100 latency and duration and severity of  
diabetis, retinopathy.
Comi  G  et  al  1986 ,  53 performed  VEP  in  85  type  I  IDDM and 
investigated  all  of  them  for  peripheral  neuropathy.  The  P100,  IPL 
latency  were  prolonged  and  P100  amplitude  decreased.  Platency 
increased with duration of diabetes. A negative correlation was found 
with  NCV.  He  concluded  the  above  results  could  be  due  to 
desynchronisation of the impulses travelling along the optic pathway.
Pierzchala  et  al,  (2002) 54,  assessed  conduction  in  central 
afferent tracts and the velocity of blood flow in pre and intracerebral  
arteries  in  63  diabetic  patients.  VEP,  BAER  and  SEP  were  studied.  
The latencies of assessed potential was significantly longer.
Fierro  et  al,199955 carried  a  neurophysiological  (SEP,  VEP) 
followup  study  in  30  diabetic  patients  ,type  I  IDDM,  to  investigate 
the  effect  of  improved glucoregulation.  Patients  showed a  decrement 
of  HbA1c and  VEP abnormalties  improved.  The results  suggest  VEP 
abnormalities  are  reversible  in  diabetic  patients  with  improved 
glycemic control.
Celiker  R  et  al,  (1996)56 investigated  in  the  absence  of 
neuropathic  symptoms.  49%  had  peripheral  NCV  slowing,  40.6%  F 
wave abnormality and 33.7% carpel tunnel syndrome.
Schneck  et  al,  (1997)57 studied  whether  specific  chromatic 
pathway  are  selectively  affected  by  short  term  variation  in  blood 
glucose level and found it to be affected.
Yin  SY  et  al,  (1991)58 found  P100  latency  to  be  particularly 
prolonged for blue color and positive correlation with blood sugar and 
duration of diabetes.
Lovasik JV et al (1988)59 examined the neural function of retina 
and  macular  cortical  pathway  by  VEP  in  30  IDDM.  Results  showed 
small  but  measurable  difference  in  amplitude  and  timing 
characteristics  of  retinal  and  cortical  potentials  for  the  test  and 
control group.
Suzuki  C  et  al,  (2000) 60 investigated  peripheral  and  central 
somotosensory conduction in patients with diabetes and found both to 
be affected.
Omer Azal, (1996) ,61 studied VEP in 45 diabeteic patients and P 
lantency prolonged in diabetics significantly.
MAS Abdel  Megeed  et  al  in  2002 64 evaluated  ERG,  and PVEP 
in 29 children with IDDM and found P100 to be significantly delayed 
in eyes of diabetic patients even in those with IDDM < 5 years.
Kate dra et  al ,65 studied VEP in 40 diabetic  patients  and found 
abnormality  in  35%  and  coexisted  with  worst  metabolic  control,  
longer duration &older patients.
Geert  Jan  Biessels  et  al  (1999) 66 compared  the  course  of 
development  of  neurophysiological  changes  in  the  central  and 
peripheral  nervous  system  in  streptozotocin  diabetic  rats.  The  study 
demonstrated  the  peripheral  impairments  develop  within  weeks  after 
diabetic  induction,  where  as  central  impairments  take  months  to 
develop. Insulin can reverse both central and peripheral aterations.
PG Ramon et al67 recorded VEP in 25 diabetic patient and 
15  control.  P100  latency  were  significantly  prolonged  and  P100 
amplitude decreased in diabetics.   
AIM OF THE STUDY
To  evaluate  visual  evoked  potential  abnormalities  in  diabetic 
patients and its relationship to peripheral neuropathy.
MATERIALS AND METHODS
The  aim  of  the  present  study  was  to  determine  the  Visual 
evoked  potential  abnormalities  in  diabetics  and  check  their 
relationship with peripheral neuropathy.
The  present  study  was  a  case  control  study  including  a  study 
group  consisting  of  34  diabetes  (19  female  and  15  males)  mean  age 
(46.8  ±  12.54) and a control  group consisting of  20 healthy subjects 
(11 females and 9 males) mean age (41.25 ±  9.39).
A  total  of  34  patients  were  chosen  according  to  inclusion  and 
exclusion  criteria  from  among  the  diabetic  patients  attending  the 
diabetology   out  patient  clinic  of  Govt.  Hospital,  Madras  Medical  
College during the period from Jan – 2005 to Aug 2005.
INCLUSION CRITERIA
1) Patients  who  were  diagnosed  to  have  diabetes  mellitus 
according  to  revised  criteria  for  diagnosing  diabetes  issued  by 
the  consensus  panel  of  experts  from the  National  Diabetic  data 
group  and  world  health  organisation  (American  Diabetes 
Association  2000)   i.e.  fasting  plasma  glucose  more  than  126 
mg  / dl  or 2 hr post prandial plasma group more than  200mg /  
dl.
2) Patients on regular treatment. 
3) Age 18 to 60 years 
EXCLUSION CRITERIA
1) Patients with diabetic retinopathy and maculopathy
2) Long standing hypertension
3) Consuming alcohol > 100ml / day
4) Those with peripheral nervous system disease unrelated to 
diabetes mellitus.
5) Cataract, glaucoma, Vitreous opacities, or any evidence of 
optic neuropathy.
6) Past history of Cerebrovascular accident. 
All  patients  were  either  NIDDM  (31)  or  IDDM  (3)  proved  by 
blood  glucose  studies.  The  duration  of  diabetes  ranged  from  3-20 
years.  Fasting  blood  glucose  level  was  estimated  prior  to  recording 
VEP.  Detailed  opthalmological  check  up  of  all  patients  was  done 
which included, visual acuity,  recording of ocular tension and fundus 
examination  under  full  mydriasis.  Only  those  patients  with  normal 
visual  acuity  at  base  line  were  included  in  the  study.  Clinical 
evidence  of  peripheral  neuropathy  was  sought  for  by  means  of 
pinprick  testing,  cottons  touch  and  vibration  testing  with  128 tuning 
fork.   Motor  power  and  reflexes  were  studied  for  evidence  of  motor 
neuropathy.
Visual  evoked  potentials  were  recorded  with  RMS  equipment, 
both  eyes  were  stimulated  separately  by  checkerboard  pattern  size 
8 x 8 reversal  at  1.7/sec.   The screen was placed at  the 1 meter  from 
the nasion.  The response was recorded by surface electrode that were 
placed  at  the  occipital  region,  the  active  one  week  being  placed  Oz 
and reference  at  Fz.  Patients  were  advised  to  come  without  applying 
oil  to  scalp  and   to  shampoo  the  hair  and  dry.   Preparations  of  skin 
was  done  by  abrading  and  degreasing.   The  aim  was  to  achieve 
maximal  stimulation  of  the  foveal  and  parafoveal  fibres  at  75% 
contrast  and  reversal  rate  of  1.2Hx.  Uniform  illumination  was 
maintained  in  the  laboratory  and  electrode  impedance  was  kept  less 
than 5 ohms.  An average of  200 sweeps  was  given to  each eye.  This 
was  repeated  twice  and  the  averages  of  were  superimposed  to 
demonstrate reproducibility.  Any difference of more than 3 ms in the 
latencies  between  trials  were  not  included.  The  peak  P  100  latency 
and amplitude were studied.
The  Right  median  and  common  peroneal  nerve  motor  and 
sensory  conduction  were  studied  recording  the  distal  latency,  CMAP 
and Nerve conduction velocity. 
RESULTS
Students t – test was used to statistically analyze for significance in 
difference in VEP in diabetics and controls  
1)  Distribution of cases and control
Sex Cases Control
Male 15 9
Female 19 11
Total 34 20
Fig.1      Distribution of Cases and Control
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2) P 100 LATENCY
P 100 
Latency
Cases Control
P ValueMean SD Mean SD
Right 95.81 7.34 94.17 4.55 0.356
Left 95.10 5.30 94.25 3.41 0.522
Mean 95.48 5.65 94.21 3.61 0.370
Fig.2        P100 Latency
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No  statistically  significant  difference  in  P  100  Latencies  of 
cases and control.
3) P 100 AMPLITUDE
P 100 
Amplitude
Cases Control
P 
ValueMean SD Mean SD
Right 3.90 2.17 4.43 2.16 0.384
Left 4.27 2.43 4.43 2.33 0.813
Mean 4.09 2.25 4.43 2.19 0.582
Fig.3     P100 Amplitude
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No  statistically  significant  difference  in  P  100  Amplitude  of 
cases and control.
4) DIFFERENCE IN P 100 LATENCY IN MALES / FEMALES
Mean P 100 Latency
Sex
Cases Control
P ValueMean SD Mean SD
Male 96.94 5.16 94.29 3.52 0.185
Female 94.33 5.89 94.14 3.85 0.925
Fig.4      Difference in P100 Latency Males & Females
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5)  PERIPHERAL  NEUROPATHY  WITH  RELATION  TO 
DURATION OF DIABETES
Years of
Diabetes
Number of Cases
No -Neuropathy Neuropathy Total
0-5 10 3 13
5-10 6 3 9
10-15 2 4 6
15-20 - 6 6
Fig.5.Peripheral  Neuropathy  With  Relation  To  Duration  Of 
Diabetes
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6) P  100  LATENCY  IN  CASES  WITH  NEUROPATHY  &  NO 
NEUROPATHY
P 100 Latency
No 
Neuropathy Neuropathy
P Value
Mean SD Mean SD
Right 98.05 5.88 93.41 8.18 0.064
Left 96.25 5.25 93.44 5.01 0.086
Mean 97.31 4.96 93.43 5.82 0.046*
 Fig.6. P 100 Latency in Cases with Neuropathy & No Neuropathy
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P 100 Latency was smaller in patients with peripheral Neuropathy 
(P < 0.05).
7) P  AMPLITUDE  IN  CASE  WITH  NEUROPATHY  AND  NO 
NEUROPATHY
P 100 
Amplitude
No 
Neuropathy Neuropathy
P Value
Mean SD Mean SD
Right 4.74 2.49 2.99 1.22 0.013
Left 5.31 2.65 3.11 1.51 0.006
Mean 5.03 2.54 3.05 3.61 0.008
Fig.7. P Amplitude in Case with Neuropathy and No Neuropathy
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Significant  (P  <.01)  reduction  in  P  amplitude  of  patients  with 
Neuropathy compared to without Neuropathy.
8) P  100  LATENCY  AND  AMPLITUDE  CORRELATION 
WITH DURATION OF DIABETES 
Diabetes in 
Years
P –Latency P –Amplitude
Mean SD Mean SD
< 5            94.82 4.74 5.47 2.62
5-10 99.26 5.05 3.09 1.71
10-15 91.41 5.67 4.10 1.10
15-20 95.33 6.09 2.58 1.26
Fig. 8 P 100 Latency and Amplitude Correlation with Duration Of 
Diabetes 
P-Latency Correlation with Duration of 
Diabetes
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By  Annova  (Multiple  range  tests:  student  newman  kauls  test)  no 
correlation P100Latency/Amplitude with duration of diabetes . 
9) P 100 INTER PEAK LATENCY
INTER PEAK LATENCY
Mean SD P –Value 
Cases 4.29 4.22
0.041
Control 2.05 2.87
Fig. 9      P100 Inter Peak Latency
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Inter  Peak  Latency  shows  significant  difference  (P  <  0.05)  between 
cases and  control
10) GENDER DIFFERENCE IN P100 LATENCY.
Sex
Diabetes Control
P value
Mean SD Mean SD
Male 96.9 5.16 94.20 3.52 0.165
Female 94.3 5.89 94.14 3.85 0.92
Fig.10.      Gender Difference in P100 Latency
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DISCUSSION
Evoked potentials  are simple,  sensitive and objective technique 
for  evaluating  impulse  conduction  along  the  central  nervous  system 
pathway. 
P 100 Latency:
Evoked potential abnormalities have been described in Diabetes 
Mellitus  but  the  proportion  of  patients  with  increased  latencies  of 
visual  P-100  is  variable  ranging,  9%  to  77%  (5,6,11,51)  .Such  high 
variability  could  be  explained  by  several  factors,  such  as  criteria  of 
ascertainment  inclusions or  diagnosis,  the  presence of  retinopathy or  
peripheral  neuropathy  and  the  difference  in  stimulus  recording 
conditions.
In  our  study  the  mean  P  100  Latency  of  cases  was  (95.48  + 
5.65) greater than the control (94.21 +3.61) but the difference was not  
statistically  significant.  Similar  was  the  observation  of  Thomas  SV 
et  al52,  Oziegler27,  Milligen et  al49.  Only 11.8% of the cases  4/84 had 
P  100  Latency  prolongation  in  the  abnormal  range  i.e.  more  than 
2.5SD  above  the  mean  P100  control  (94.21  +  9.02  =  103.23). 
However most of the studies have demonstrated significant increment 
in P100 Latency in the diabetic compared with non diabetic controls. 
Algan  et  al4 found  prolongation  of  P-100  Latency  in  50  diabetic 
patients  of  which 6  of  them had  diabetic  retinopathy.  Mariani  et  al 22 
found  prolongation  of  P  100  in  35 diabetic  patients  but  they  did  not 
have retinopathy. Ponte F et al 23 reported prolongation of VEP latency 
in  50  asymptomatic  IDDM  without  retinopathy.  Puvanendrian  K  et 
al6,  Cirillo  D  et  al 24 &  Anastasi  M  et  al 50 also  reported  VEP 
abnormalities  in  diabetic  patients.   Although collier  et  al  found VEP 
abnormalities  in  diabetic  patients  with  retinopathy  they  did  not  find 
any abnormality in other patients without retinopathy. Yaltkaya et al 26 
found  prolongation  of  N  140  latency  and  N  70,  N140  inter  peak 
latencies  as  well  as  P  100  latencies  and  they  explained  it  with  
existence  of  retrochiasmal  involvement.  Bortek  L  et  al 70 found  77% 
VEP abnormalities  and did not find any correlation with retinopathy. 
Sima et al have recently shown that diabetic BB rat develop a central 
sensory  neuropathy  in  which  there  are  prolonged  latencies  of  VEP 
related to axonopathy of optic nerve fibers.
P 100 AMPLITUDE:
In our study P 100 amplitude mean in diabetic (4.09 + 2.25) was 
lower  than  the  control  (4.43  +  2.19)  but  the  difference  was  not 
statistically  significant.  Significant  low  mean  P  amplitude  has  been 
observed by Lip P Yang Y et al 36. & Panch et al39. 
P  100  AMPLITUDE  and  LATENCY  in  relationship  to  Peripheral 
Neuropathy.
In our study 47% of patients (16/34) had peripheral  neuropathy 
based on the presence of median or peroneal nerve motor or sensory. 
Velocity  or  latency  below  the  lower  limit  of  normal.  There  was  no 
correlation  between  prolongation  of  P  100  latency  and  presence  of 
peripheral  neuropathy.  The  mean  P  100  in  patients  with  peripheral 
neuropathy  was  smaller  (  93.43  ±  5.82)  than  in  patients  without 
evidence of neuropathy (97.31  ±  4.96) Comi G et  al   had observed a 
negative  correlation  at  30’  check  size  between  P  100  latency  and 
motor  sensory  nerve  conduction  velocity  in  all  examined  nerves. 
Khardori  et  al  studied  34  IDDM  patients  and  did  not  find  any 
relationship  with  VEP  abnormalities  and  presence  of  peripheral 
neuropathy.  Yaltkaya  et  al 26 also  reported  no  correlation  in  P100 
latency  in  25  diabetics  he  studied  with  sural  nerve  conduction 
abnormalities.  The  same was  also  stated  by Algan  M et  al 4,  Uberrall 
MA et al32, Pozzessere et al29 identified significant abnormalities both 
in  peripheral  and  central  nerve  conduction  in  IDDM  and  NIDDM 
subjects,  but  no  correlation  between  these  phenomena  were 
performed. In contrast to the above studies other authors Puvanendran 
et  al,  Mariani  E  et  al22.  LiP  yangy36 and  Akinci  et  al48 have  found 
positive  correlation  between  abnormalities  in  peripheral  nerve 
conduction and changes in P 100 Latency.
In our study mean P 100 amplitude was significantly (P < 0.01) 
reduced in those with peripheral  neuropathy (3.03  ±  1.26) than those 
without (5.03 ±  2.54) this has not been observed in other studies. 
DURATION OF DIABETES
Our  study  did  not  show  any  linear  correlation  between  P  100 
latency and amplitude and duration of diabetes. (Table –8) .Of the 10 
studies  that  have  examined  this  association  significant  positive 
correlation with duration of diabetes was described only in 3 reports.  
Prolonged P 100 latency have been found within 4 years of diagnosis 
in  patients  with  IDDM  and  NIDDM  and  in  different  study  within  6 
years  of  onset  of  IDDM.  Alteration  of  P  100  latencies  have  been 
demonstrated within a few weeks of diagnosis of IDDM.
Over  all  the  evidence  for  an  association  between  duration  of 
diabetes  and  VEP  abnormalities  is  limited  in  keeping  with  the 
presence  of  P  100  abnormalities  in  people  with  recently  diagnosed 
diabetes.  Few have  reported  no correlation  with  duration  of  diabetes 
as was our observation, Algan et  al 4,  G.  Pozzessere et  al 29,  Uberall32, 
Khardori et al41, Collier et al45.
TYPE OF DIABETES
In  our  study  IDDM patients  constituted  only  9% (3/34)  of  the 
study  group  and  rest  where  NIDDM.  Among  the  3  IDDM  one  had 
prolonged  P  100  latency  (33%).  Among  the  31  NIDDM  3  had 
prolonged latency (9.7%). Being a small  study group it  is  difficult  to 
give  correct  interpretation  for  this  finding.   More  et  al  reported  that  
39%  of  their  NIDDM  group  had  P  100  Latencies  more  than  2  SD 
greater  than  non  diabetic  control.   Pozzessere  et  al 28 found  P  100 
Latency  changed  in  a  similar  proportion  of  each  group.  (21  %  of 
NIDDM  &  18%  of  IDDM).  Algan  et  al 4 also  found  no  significant 
difference between subjects with  IDDM and NIDDN,  demonstrating 
increased latency in approximately 28% of each group.
GLYCEMIC CONTROL
In  our  study  long  term  glycemic  control  by  glycosylated 
hemoglobin  was  not  estimated.   In  some  study  evoke  potential  have 
been  correlated   with  hyperglycemia  and  in  others,  the  evidence  for 
an  association  with  glycemic  control  in  less  compelling  than  for 
duration  of  diabetes  with  only  one  of  the  ten  studies  demonstrating,  
Marian  et  al,  significant  correlation.  Ziegler  et  al 27 had  VEP 
measurements  in  poorly  controlled  diabetics  before  and  after  three 
days  of  insulin  to  achieve  normoglycemia  and  demonstrated 
significant  shortening  in  P  100  latency  although  these  still  remained 
significantly  prolonged  in  comparison  with  non  diabetic  value.  In 
view of the rapid improvement author proposed that the changes in P 
100  latency  resulted  from  metabolic  effects  rather  than  structural 
changes as suggested by many others.
AGE OF PATIENTS
Our  study  was  confined  to  patients  more  than  18  years.  But  there  are 
several  studies  that  have assessed VEP P 100 in  children and adolescence with  
IDDM,  the  majority  of  whom  had  no  overt  retinopathic  changes.  Two  studies 
reported  prolonged  latency  30%  and  27%  both  in  Pre  and  post  pubertal 
diabetic children which are comparable in magnitude to the results observed in 
adult  with  IDDM.   However  in  a  different  study,  Lovasit  et  al 59 observed  no 
changes in P 100 latency in a chort of young patients with IDDM.  In our study  
P  100  latency  increased  with age  but  correlation  was  better  in  controls  (34%) 
compared to cases.
INTER PEAK LATENCY
The  P  100  inter  ocular  latency  difference   was  more  in  diabetic  
compared to control and was statistically significant (table-9).              Pan CH 
et  al39 had  analysed  this  and  did  not  find  statistically   significant  different  
between IDDM and age matched control group.
SEX OF PATIENT
In  our  study  P  latency  was  longer  in  adult  male  compared  to  female  in  both 
diabetic  and  control  (table  –10)  but  statistically  no  significant  difference.  The 
same was observed in normal adult by Guthkel CH              et al 64.
SUMMARY 
1) No significant prolongation of P 100 latency in diabetic patients 
compared  to  control.  11.8% of  cases  (4/34)  had  P  100  latency 
prolongation > 2.5SD (94.21 + 9.02) above the mean of control.  
(1 SD = 3.61)
2) P 100 Latency did not show any correlation with the presence of 
peripheral neuropathy.
3) P  100  amplitude  was  significantly  decreased  in  those  with 
peripheral neuropathy compared to those without neuropathy.
4) There was no correlation with duration diabetes. 
5) Inter  Peak  Latency  difference  was  more  in  diabetics  compared 
to controls and was statistically significant. 
CONCLUSION
VEP abnormalities are present in diabetic patients in the form of 
prolongation  of  P100  latency  and  decreased  P100  amplitude  but  are 
not statistically significant.
P  100  amplitude  is  decreased  in  patients  with  peripheral 
neuropathy.  
S.No Name Age Sex Case/
Control
Duration 
of 
Diabetes
Neuropathy P LAT R P LAT L MEAN 
PLAT
P 
AMP
 R
P AMP 
L
MEAN 
P AMP
IPL
1 Veshalakshi 63 F 1 1 1 101.30 91.30 96.30 3.64 4.12 3.88 10.00
2 Sudha 37 F 1 1 1 99.40 99.40 99.40 6.39 6.74 6.57 0.00
3 Sundari 25 F 1 1 1 91.30 96.30 93.80 4.22 4.66 4.44 5.00
4 Senthamari 52 M 1 1 1 90.60 90.60 90.60 8.69 9.98 9.34 0.00
5 Karthikeyan 22 M 1 1 1 102.50 107.50 105.00 3.20 3.40 3.30 5.00
6 Lalitha 40 F 1 1 1 92.50 91.90 92.20 6.89 7.39 7.14 0.60
7 Muthu Lakshmi 42 F 1 1 1 103.80 90.40 97.10 3.62 3.19 3.41 13.40
8 Kandan 50 M 1 1 1 98.80 99.40 99.10 3.80 4.10 3.95 0.60
9 Kali Muthu 55 M 1 1 1 90.63 93.75 92.19 9.12 9.40 9.26 3.12
10 Devaki 29 F 1 1 1 90.60 93.80 92.20 9.10 10.60 9.85 3.20
11 Vasanth 23 M 1 2 1 95.60 95.00 95.30 3.19 6.04 4.62 0.60
12 Rajendran 47 M 1 2 1 105.00 98.10 101.55 1.00 2.10 1.55 6.90
13 Jayachandran 60 M 1 2 1 101.90 101.30 101.60 1.60 2.46 2.03 0.60
14 Pachiamma 50 F 1 2 1 110.00 106.90 108.45 1.75 2.10 1.93 3.10
15 Indirani 45 F 1 2 1 96.90 90.00 93.45 6.13 6.56 6.35 6.90
16 Naseema 25 F 1 2 1 98.80 99.40 99.10 3.80 4.16 3.98 0.60
17 Adhi Lakhsmi 45 F 1 3 1 91.90 94.40 93.15 5.10 3.75 4.43 2.50
18 Naga Booshan 50 M 1 3 1 103.40 98.80 101.10 4.16 4.80 4.48 4.60
19 Gopala Krishnan 60 M 1 1 2 86.30 95.00 90.65 3.98 4.26 4.12 8.70
20 Gandhimathi 39 F 1 1 2 86.30 88.10 87.20 2.92 3.21 3.07 1.80
21 Manjula 42 F 1 1 2 103.80 90.00 96.90 3.60 1.92 2.76 13.80
22 Saraswathi 58 F 1 2 2 90.60 96.90 93.75 1.06 1.47 1.27 6.30
23 Govindhan 60 M 1 2 2 108.80 98.80 103.80 2.20 2.16 2.18 10.00
24 Prabhu 52 M 1 2 2 101.30 91.30 96.30 3.64 4.12 3.88 10.00
25 Sundara Moorthy 53 M 1 3 2 92.50 93.10 92.80 2.58 3.89 3.24 0.60
26 Saraswathi 58 F 1 3 2 84.40 85.60 85.00 5.08 6.81 5.95 1.20
27 Rani 53 F 1 3 2 88.10 88.10 88.10 3.40 2.40 2.90 0.00
28 Nagapooja 59 F 1 3 2 88.10 88.50 88.30 3.40 3.80 3.60 0.40
29 Renganayagi 60 F 1 4 2 105.00 103.80 104.40 4.80 3.80 4.30 1.20
30 Selvarajan 52 M 1 4 2 85.00 97.50 81.25 1.00 1.40 1.20 12.00
31 Israel 59 M 1 4 2 88.80 95.10 91.95 1.44 3.85 2.65 6.30
32 Ramachandran 60 M 1 4 2 103.10 98.80 100.95 1.95 1.38 1.67 4.30
33 Jagadeeswari 60 F 1 4 2 88.00 89.50 88.75 2.40 1.21 1.81 1.50
34 Anjali 50 F 1 4 2 94.40 95.00 94.70 3.60 4.10 3.85 0.60
35 Anaki 45 F 2 0 1 89.40 88.80 89.10 3.81 2.24 3.30 0.60
36 Meenakshi 50 F 2 0 1 82.50 94.40 88.45 2.57 2.29 2.43 11.90
37 Poongodi 45 F 2 0 1 96.90 97.50 97.20 8.49 7.39 7.94 0.60
38 Chitra 45 F 2 0 1 96.90 97.50 97.20 8.41 7.39 7.90 0.60
39 Malli 40 F 2 0 1 100.00 99.40 99.70 4.14 3.07 3.60 0.60
40 Chinnian 42 M 2 0 1 93.80 96.30 95.05 1.38 1.47 1.42 2.50
41 Lakshmanan 36 M 2 0 1 94.40 91.30 92.85 1.91 1.87 1.89 3.10
42 Gopalan 58 M 2 0 1 95.60 95.60 95.60 7.05 6.24 6.65 0.00
43 Amkiah 44 M 2 0 1 99.40 99.40 99.40 3.02 2.65 2.84 0.00
44 Vijaya 30 F 2 0 1 91.90 92.50 92.20 5.85 6.91 6.38 0.60
45 Maruthiayi 55 F 2 0 1 89.40 91.90 90.65 2.97 2.50 2.74 2.50
46 Kannamal 47 F 2 0 1 99.40 94.40 96.90 4.95 7.03 5.98 5.00
47 Rajendran 39 M 2 0 1 100.00 100.00 100.00 5.27 5.83 5.55 0.00
48 Priya 30 F 2 0 1 91.30 91.90 91.60 3.54 3.13 3.34 0.60
49 Raman 30 M 2 0 1 90.60 89.40 90.00 6.38 6.40 6.39 1.20
50 Ramadoss 36 M 2 0 1 94.40 90.60 92.50 4.80 5.00 4.90 3.80
51 Mohan 25 M 2 0 1 91.30 91.30 91.30 1.91 1.87 1.85 0.00
52 Ramesh 50 M 2 0 1 91.90 92.00 91.95 5.85 6.91 6.38 0.10
53 Gheetha 50 F 2 0 1 94.40 96.30 95.35 1.38 1.47 1.42 1.90
54 Valliammal 58 F 2 0 1 99.90 94.40 97.15 4.95 7.03 5.99 5.50
Case  1, Control  2.
Duration of Diabetes 
0  No diabetes, < 5  1, 5 – 10  2, 10 – 15  3, 15 – 20  4
No Neuropathy (NN)  1
Neuropathy Present (PN)  2
P LAT R  P 100 LATENCY RIGHT
P LAT L  P 100 LATENCY LEFT
P AMP L  P 100 AMPLITUDE LEFT
P AMP R  P 100 AMPLITUTDE RIGHT
IPL  INTER PEAK P100 LATENCY
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